Detalhe da pesquisa
1.
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Hematol Oncol
; 40(4): 801-804, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313381